Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Coiffier

Showing results (191-200 of 249) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|June 2, 2012
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trialRuth Pettengell, Bertrand Coiffier, Geetha Narayanan, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Hematological Oncology|July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphomaBarbara Pro, Steven M Horwitz, H Miles Prince, et al.
Blood|February 23, 2008
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trialsNathalie Mourad, Nicolas Mounier, Josette Brière, et al.
Haematologica|January 28, 2017
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyVincent Ribrag, Won Seog Kim, Reda Bouabdallah, et al.
Hematological Oncology|May 4, 2018
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomesLauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, et al.
Journal of Hematology & Oncology|October 24, 2012
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trialPier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, et al.
British Journal of Haematology|April 23, 2010
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 studyBertrand Coiffier, Nedjad Losic, Birgitte Biilmann Rønn, et al.
Haematologica|January 29, 2016
The European Hematology Association Roadmap for European Hematology Research: a consensus documentAndreas Engert, Carlo Balduini, Anneke Brand, et al.
Leukemia & Lymphoma|March 29, 2011
Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometryDelphine Rolland, Ali Bouamrani, Rémi Houlgatte, et al.
Pageof 25

Showing results (191-200 of 249) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|June 2, 2012
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trialRuth Pettengell, Bertrand Coiffier, Geetha Narayanan, et al.
International Journal of Environmental Research and Public Health|March 19, 2020
Resources-Stratified Guidelines for Classical Hodgkin LymphomaAllan Relecom, Massimo Federico, Joseph M Connors, et al.
Hematological Oncology|July 13, 2016
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphomaBarbara Pro, Steven M Horwitz, H Miles Prince, et al.
Blood|February 23, 2008
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trialsNathalie Mourad, Nicolas Mounier, Josette Brière, et al.
Haematologica|January 28, 2017
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyVincent Ribrag, Won Seog Kim, Reda Bouabdallah, et al.
Hematological Oncology|May 4, 2018
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomesLauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, et al.
Journal of Hematology & Oncology|October 24, 2012
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trialPier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, et al.
British Journal of Haematology|April 23, 2010
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 studyBertrand Coiffier, Nedjad Losic, Birgitte Biilmann Rønn, et al.
Haematologica|January 29, 2016
The European Hematology Association Roadmap for European Hematology Research: a consensus documentAndreas Engert, Carlo Balduini, Anneke Brand, et al.
Leukemia & Lymphoma|March 29, 2011
Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometryDelphine Rolland, Ali Bouamrani, Rémi Houlgatte, et al.
Pageof 25